In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

被引：6

作者：

Kaushik, Amit ^{[1
]}

Ammerman, Nicole C. ^{[1
]}

Martins, Olumide ^{[1
]}

Parrish, Nicole M. ^{[2
]}

Nuermberger, Eric L. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD 21205 USA

[2] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 06期

基金：

美国国家卫生研究院;

关键词：

Mycobacterium abscessus; omadacycline; drug susceptibility assay; eravacycline; tetracyclines; tigecycline; RAPIDLY GROWING MYCOBACTERIA; NONTUBERCULOUS MYCOBACTERIA; LUNG-DISEASE; TIGECYCLINE; EPIDEMIOLOGY; INFECTIONS; GENE;

D O I：

10.1128/AAC.00470-19

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for M. abscessus infections.

引用

页数：5

共 34 条

[1] rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp nov., Mycobacterium phocaicum sp nov and Mycobacterium aubagnense sp nov.
Adékambi, T
Berger, P
Raoult, D
Drancourt, M
[J]. INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, 2006, 56 : 133 - 143
[2] Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA
Adjemian, Jennifer
Frankland, Timothy B.
Daida, Yihe G.
Honda, Jennifer R.
Olivier, Kenneth N.
Zelazny, Adrian
Honda, Stacey
Prevots, D. Rebecca
[J]. EMERGING INFECTIOUS DISEASES, 2017, 23 (03) : 439 - 447
[3] Cavusoglu C, 2012, NEW MICROBIOL, V35, P73
[4] Clinical and Laboratory Standards Institute, 2011, M24A2 CLSI, V31
[5] Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease
Ferro, Beatriz E.
Srivastava, Shashikant
Deshpande, Devyani
Pasipanodya, Jotam G.
van Soolingen, Dick
Mouton, Johan W.
van Ingen, Jakko
Gumbo, Tawanda
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 2895 - 2900
[6] US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary
Floto, R. Andres
Olivier, Kenneth N.
Saiman, Lisa
Daley, Charles L.
Herrmann, Jean-Louis
Nick, Jerry A.
Noone, Peadar G.
Bilton, Diana
Corris, Paul
Gibson, Ronald L.
Hempstead, Sarah E.
Koetz, Karsten
Sabadosa, Kathryn A.
Sermet-Gaudelus, Isabelle
Smyth, Alan R.
van Ingen, Jakko
Wallace, Richard J.
Winthrop, Kevin L.
Marshall, Bruce C.
Haworth, Charles S.
[J]. THORAX, 2016, 71 (01) : 88 - 90
[7] Gotfried MH, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01135-17, 10.1128/aac.01135-17]
[8] Mycobacterium abscessus and Antibiotic Resistance: Same As It Ever Was
Griffith, David E.
[J]. CLINICAL INFECTIOUS DISEASES, 2019, 69 (10) : 1687 - 1689
[9] Mycobacterium abscessus "Pleased to Meet You, Hope You Guess My Name..."
Griffith, David E.
Brown-Elliott, Barbara A.
Benwill, Jeana L.
Wallace, Richard J., Jr.
[J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (03) : 436 - 439
[10] Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan
Huang, Chien-Wen
Chen, Jiann-Hwa
Hu, Shiau-Ting
Huang, Wei-Chang
Lee, Yen-Chung
Huang, Chen-Cheng
Shen, Gwan-Han
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 41 (03) : 218 - 223

← 1 2 3 4 →